Technical Analysis for CALC - CalciMedica, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| NR7 | Range Contraction | 1.40% | |
| NR7-2 | Range Contraction | 1.40% | |
| Narrow Range Bar | Range Contraction | 1.40% | |
| Doji - Bullish? | Reversal | 1.40% | |
| Wide Bands | Range Expansion | 1.40% | |
| Down 3 Days in a Row | Weakness | 1.40% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.76% | |
| NR7 | Range Contraction | -0.76% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 14 hours ago |
| 60 Minute Opening Range Breakout | about 15 hours ago |
| Rose Above 10 DMA | about 15 hours ago |
| Up 2% | about 15 hours ago |
| Fell Below Previous Day's Low | about 16 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/13/2024
CalciMedica, Inc. Description
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of calcium release-activated calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in four completed efficacy clinical trials. Auxora is in development for acute pancreatitis and asparaginase-associated pancreatitis. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Medication Inflammatory Diseases Abdominal Pain Pancreatitis Acute Pancreatitis Asparaginase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.59 |
| 52 Week Low | 1.0 |
| Average Volume | 21,592 |
| 200-Day Moving Average | 3.73 |
| 50-Day Moving Average | 4.54 |
| 20-Day Moving Average | 5.05 |
| 10-Day Moving Average | 5.64 |
| Average True Range | 0.43 |
| RSI (14) | 62.96 |
| ADX | 21.66 |
| +DI | 26.09 |
| -DI | 18.52 |
| Chandelier Exit (Long, 3 ATRs) | 4.99 |
| Chandelier Exit (Short, 3 ATRs) | 5.29 |
| Upper Bollinger Bands | 6.39 |
| Lower Bollinger Band | 3.71 |
| Percent B (%b) | 0.7 |
| BandWidth | 53.19 |
| MACD Line | 0.38 |
| MACD Signal Line | 0.33 |
| MACD Histogram | 0.0426 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.82 | ||||
| Resistance 3 (R3) | 5.81 | 5.73 | 5.78 | ||
| Resistance 2 (R2) | 5.73 | 5.68 | 5.74 | 5.77 | |
| Resistance 1 (R1) | 5.66 | 5.64 | 5.70 | 5.67 | 5.76 |
| Pivot Point | 5.58 | 5.58 | 5.60 | 5.59 | 5.58 |
| Support 1 (S1) | 5.51 | 5.53 | 5.55 | 5.52 | 5.43 |
| Support 2 (S2) | 5.43 | 5.49 | 5.44 | 5.42 | |
| Support 3 (S3) | 5.36 | 5.43 | 5.41 | ||
| Support 4 (S4) | 5.37 |
